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Summary
A new anticoagulant, recombinant hirudin, was given to
hea"hy volunteers (5 per test dose) in single .intravenous
doses of 0,01, 0,02, 0,04, 0,07 and 0,1 mg/kg to study its
anticoagulant effects, how it was tolerated and its pharma-
cokinetics. Hirudin proved to be a potent anticoagulant with
important effects on thrombin (increase in thrombin time and
partial thromboplastin time). The maximum pharmacodynamic
effect was achieved with the 0,07 mg/kg dose, and upwards.
All doses of the compound were tolerated without side-
effects. The mean elimination half-life is about 1 hour. Mean
total clearance and volume of distribution are approximately
190 ml/min and 14 I, respectively. Hirudin obeys first-order
pharmacokinetics.
S Atr Med J 1990; 78: 268-270.
In 1884, J. B. Haycraft, working in Strasbourg, recognised
that medicinal leeches (Hirudo medicinalis) contained a sub-
stance with anticoagulant properties. The pure anticoagulant
substance from medicinal leeches was isolated in the late
1950so Called hirudin, it was found to be a selective thrombin
inhibitor with polypeptide structure. It is produced by the
peripharyngeal glands of medicinal leeches. Hirudin is a poly-'
peptide containing 65 amino acids with a molecular weight of
about 8000. 1 Early studies were done with natural hirudin;2
however, medicinal leeches are an endangered species, hence
natural hirudin is not available in adequate quantities for
therapeutic use. t
Progress in genetic engineering resulted in the availability of
larger amounts of this anticoagulant. Recombinant hirudin has
pharmacological properties similar to those of natural hirudin
and is also a highly potent antithrombotic agent, which has
been well tolerated in vivo in animal studies.3
A study was undertaken to investigate the tolerance,
pharmacodynamics and pharmacokinetics of increasing doses
of hirudin in healthy men. .
Subjects and methods
Twenty-five consenting healthy male volunteers were recruited
to participate in this study, which was performed at the
Hoechst Research Clinic, Department of Pharmacology, Uni-
versity of the Orange Free State, with approval from the
Medicines Control Council of South Mrica and the University
of the Orange Free State Ethics Committee.
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Before being entered into the study, volunteers were screened
by means of a physical examination and clinical chemistry
measurements, haematological tests and urinalysis.
Five of the 25 volunteers received 0,01 mg/kg of the
recombinant hirudin intravenously. Tolerance, effects on
coagulation and pharmacokinetic values were measured. Doses
of 0,02 mg/kg, 0,04 mg/kg, 0,07 mg/kg and 0,1 mg/kg were
then administered sequentially to 4 sets of 5 different volunteers
after it had been ascettained that the previous lower dose was
well tolerated.
Volunteers had to have fasted before reporting at 07hOO to
the clinic where they spent 12 hours. Medication was admini-
stered intravenously over 2 minutes into an arm and blood for
the various tests was taken from the opposite arm.
The following variables were investigated:
Hirudin plasma and urine concentrations
Blood specimens were taken before medication and 10, 20,
30, 60, 90, 120, 180, 240, 300, 360 minutes and 24 hours after
medication.
Fractionated urine specimens were collected 0-2, 2-4, 4-6,
6-8,8-12, 12-18, 18-24 and 24-48 hours after medication.
Hirudin concentrations in serum and urine were measured
by means ofbioassay accordiIig to Griessbach et a/.4 •
Coagulation
Thrombin time (TT) was measured by standard methods
and partial thromboplastin time (PIT) by using Platelin-plus
Activator (General Diagnostics, Morris Plains, New Jersey,
USA).
Pharmacological safety
Measurement of plasma glucose, creatinine,- sodium, potas-
sium, uric acid, alanine aminotransferase, aspartate amino-
transferase, alkaline phosphatase, total bilirubin, -y-glutamyl
transferase and total protein values was performed before and
24 hours after medication by routine methods.
Haematological status (haemoglobin, haematocrit, red cell
count, mean corpuscular haemoglobin, white blood cells and
differential count, platelet count, and erythrocyte sedimentation
rate) was measured at the same time as clinical chemistry tests
were conducted.
Physical examination was performed before and 24 hours
after medication. Recumbent systolic and diastolic blood pres-
sure and heart rate were measured before and 15, 30, 60, 90,
120, 180, 240, 300,360 minutes and 24 hours after medication.
ECGs were performed immediately before and 1, 6 and 24
hours after medication.
Maximum hirudin plasma concentration (Cmax) and time to
maximum concentrations (Tmax) were read directly from the
hirudin plasma concentration-time curves.
Areas under the plasma concentration-time data pairs
(AUCo--t,s h and AUCo--s h) were calculated according to the
linear trape'zoidal rule.
Initial and second elimination half-lives (tl!;& and tl!.b) were
calculated by the adjustment of a double exponential tunction
to the appropriate phases of the log-linear plasma concen-
tration-time proflle. The method of least squares was used for
the adjustment. The value of z in the function Ce-z, was thus
found and tl! calculated from:
tv. = 0,6931z.
Total clearance (Cl-tot) was calculated from the equation:
Cl-tot = dose/AUCo_ 5b'
Total mean time (MT-vss) was calculated from:
MT-vss =PAUC1 O_ibIPAUCo O-Sb
where PAUC1 and PAUCo are the first and zero order pros-
pective AUCs for the period 0 - 5 hours.5
Total volume of distribution (V-ss) was calculated from:
V-ss = Cl-tot.MT-vss.
Results
The mean serum concentrations of hirudin for each of the 5
doses are shown in Fig. 1.
The mean ± SD values and ranges of the pharmacokinetic
parameters of hirudin for the various doses are listed in
Table I.
The mean ± SD total urinary excretion (from 0 - 48 hours
after medication) of hirudin for the various doses is given in
Table n.
Fig. 2 reflects the relationship between dose and AUC~I,5b.













Fig. 1. Hirudin plasma concentrations for doses of 0,01 - 0,1
mg/kg.
The effects of hirudin on PTT and TT are shown in Table
In. Fig. 3 reflects the relationship between hirudin plasma
concentrations and TT and PTT.
Safety measurements (physical examination, blood pressure,
clinical chemistry tests and haematological values) were not
affected by the administration of hirudin. No trends or panems
of change associated with medication with hirudin could be
discerned with regard to these variables.
TABLE I. SUMMARY OF MEAN VALUES ± SO AND RANGES OF THE PHARMACOKINETIC MEASUREMENTS
OF HIRUDIN FOR THE VARIOUS DOSES
0,01 mg/kg 0,02 mg/kg 0,04 mg/kg 0,07 mg/kg 0,1 mg/kg
Cmax (ng/ml) 76,4±11,2 151±14,6* 331 ±42,5* 518 ±36,5* 859±106*
Range 63,0-89,7 135-168 281-395 461-559 752-996
AUCO•1,5h (ng.h/ml) 56,3±8,97 101±15,2 197±28,6 331 ±41,4 471 ±69,3
Range 44,7-65,4 86,0-120 175 -243 293-392 395 -550
AUCO•1,5h (ng.h/ml) t t 268±55,4 545±205 652 ±118
Range 214-347 389-890 551-834
!'h;' 0,08±0,05 0,13±O,08 0,09±0,04 0,14±0,04 0,10±O,04
Range 0,20-0,12 0,04~,24 0,05-0,15 0,09 -0,18 0,04~,14
t'h:b 1,18±0,22 1,63±O,84 0,76 ±O,18 1,70 ±1 ,45 0,82±O,19
Range 0,99-1,43 0,71-2,74 0,53-1,02 0,83-4,28 0,62-1,09
Cl-tot (ml/min) t t 197 ±37,0 174±37,6 205±441
Range 150 -246 115-216 158-256
Cl-renal (mllmin) 86,8±12,6 ·65,1 ±19,3 94,2±17,8
Range 73,9-103 33,5-81,4 72,5-115
MT-vss (h) t t 1,15 ±O,16 1,41 ±0,42 1,17±O,13
Range 0,91 -1,33 0,99-2,02 1,06-1,38
V-ss (I) t t 13,3±1,21 14,1 ±2,01 14,3±3,08
Range 11,3-14,3 11,0 -16,5 10,5-18,0
• Rrst observed concentration.
t Plasma concentrations too low for calculation.
TABLE 11. SUMMARY OF MEAN VALUES ±SD AND RANGES OF TOTAL URINARY EXCRETION OF HIRUDIN
FOR THE VARIOUS DOSES
0,01 mg/kg 0,02 mg/kg 0,04 mglkg 0,07 mg/kg 0,1 mg/kg
Hirudin (Jig) 484 ±122 560±120 1455±250 2252±901 3855±715
Range 311-640 438-758 1 126-1694 1 383-3725 2654-4567
Hirudin (% of dose) 65,5±21,3 39,1 ±10,0 47,4±7,92 41,7±13,0 49,4±8,10
Range 42,5-92,7 28,1-54,5 38,0-54,9 24,7-60,5 38,5-57,8
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Fig. 2. Relationship between AUC 0 _ 1,5 and dose of hirudin. Fig. 3. Hirudin plasma concentrations v. PT and PTT.
TABLE Ill. MEAN ± SO VALUES OF PTT AND TT(s) FOR EACH OF THE 5 DOSES
Sampling
time (h) 0,01 mglkg 0,02 mg/kg 0,04 mglkg 0,07 mg/kg 0,1 mg/kg
PTT
° 34,2±3,27 31,5±1,73 32,4±0,89 36,0±4,95 32,8±2,170;17 46,0±4,80 47,8±4,44 60,4±4,22 82,2±15,3 76,2±9,96
1 38,8±2,75 39,2±2,28 45,2±2,39 57,6±11,5 52,2·±6,72
2 37,8±2,59 36,8±2,86 38,8±2,22 51,0±12,0 44,6±5,81
5 34,2±2,39 33,6±2,51 33,8±1,30 39,8±6,54 35,6±3,29
TT
° 13,4±1,34 13,0±0,82 14,2 ±0,45 13,6±0,89 12,8 ±O,840,17 20,8±3,19 57,4±5,81 60,0' 60,0' 60,0'
1 15,5±1,92 15,8±2,17 26,2±7,76 42,4±14,4 57,2±6,26
2 14,4±1,82 14,8±1,10 16,5±0,58 18,8±1,92 21,8±6,98
5 14,6±2,07 14,0±1,00 15,4±1,14 14,2 ±0,45 14,2±1,30
• All values above SOs.
Discussion
According to the data it is clear that hirudin is eliminated by a
two-compartment body model, but the existence of a third
compartment cannot be excluded. The mean t!o;b was approxi-
mately 1 hour. Mean total clearance and total volume of
distribution were about 180 ml/min and 12 1, respectively.
The pharmacokinetic parameters emu' AU~',5b and AU~sb
were dose-related - the mean values increasing with dose in
a linear fashion. In addition, since the mean t!O. and t\6'b' total
clearance and volume of distribution remanred reasonably
constant as dose increased, it may be assumed that hirudin
obeys linear pharmacokinetics. This' was confIrmed by the fact
that the total urinary excretion ofhirudin also increased in an approxi-
mately linear fashion with an increasing dose.
The two most important pharmacodynamic parameters, PTT
and TT, were markedly elevated after injection of hirudin and
maximum values of both variables were achieved at 10 minutes,
which was the fIrst sampling time. The maximum effect on
PTT and TT was achieved as from 0,07 mg/kg. Five hours
after injection of hirudin, both parameters had returned to
baseline levels.
Bleeding time tended to increase 30 minutes after injection,
but statistical comparison with only fIve volunteers per group
is not feasible.
In conclusion it may therefore be stated that all the doses of
hirudin were tolerated very well. No signs of bleeding tenden-
cies were observed and safety measurements, such as clinical
chemistry tests and haematological values were unaffected.
Hirudin seems to obey fIrst-order kinetics and has a profound
effect on the ability of blood to coagulate after transvenous
administration, as can be seen from its effects on TT and
PTT.
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